Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | SELL | P14151 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
| ▸ | SELE | P16581 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22133743 | 0.83 | CA6 (0.39) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL765925 | 0.83 | ALDH1A1 (0.43) | ERN1CA3CA6CA5ACA9 | |
| SCHEMBL27396426 | 0.83 | TRPA1 (0.39) | ERN1CA3CA6CA5ACA9 | |
| SCHEMBL5669068 | 0.83 | MEN1 (0.40) | ERN1CA3CA6CA5ACA9 | |
| SCHEMBL16760493 | 0.79 | CYP3A4 (0.40) | ERN1CA3CA6CA5ACA9 | |
| SCHEMBL2051687 | 0.79 | EPRS1 (0.33) | ERN1CA3CA6CA5ACA9 | |
| SCHEMBL14113092 | 0.79 | DPP4 (0.37) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL22699000 | 0.79 | ALDH1A1 (0.36) | ERN1CA3CA6CA5ACA9 | |
| SCHEMBL19171723 | 0.78 | ERN1 (0.38) | ERN1CA3CA6CA5ACA9 | |
| SCHEMBL29620265 | 0.77 | ACHE (0.42) | CA3CA6CA5ACA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20220157484-A1 | POLYURETHANE, POLYURETHANE PRODUCTION METHOD, CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-05-19 | — | — | US | disclosed |
| EP-3193851-B1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3055290-B1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10202360-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| WO-2017184462-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2017-10-19 | — | — | US | disclosed |
| WO-2017172979-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE | ARAXES PHARMA LLC (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| WO-2016049568-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016044772-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| US-8110593-B2 | Phenoxymethyl imidazoline derivatives and their use as pesticides | SYNGENTA CROP PROTECTION LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100120881-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2117310-A2 | CHEMICAL COMPOUNDS | Syngeta Participations AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008098657-A2 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | ERN1 2564/4885CA3 4459/4885CA6 3275/4885 |
| US-10202360-B2 | Therapeutic compounds | EP300, BRDT, BRPF3 | ERN1 982/4885CA3 4463/4885CA6 4177/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ERN1 973/4885CA3 2848/4885CA6 3180/4885 |
| US-20170298040-A1 | THERAPEUTIC COMPOUNDS | EP300, BRDT, BRPF3 | ERN1 982/4885CA3 4463/4885CA6 4177/4885 |
| US-20100120881-A1 | CHEMICAL COMPOUNDS | AADAC, ACHE, ATL3 | ERN1 3767/4885CA3 1203/4885CA6 3142/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ERN1 973/4885CA3 2848/4885CA6 3180/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | ERN1 2401/4885CA3 3801/4885CA6 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.